BaroFold, a Boulder, Colo., biotech raised $12 million in a first round of funding. The company is developing PreEMT, a technology that uses high levels of fluid pressure to “unclump” biotech-drug proteins that have stuck together and to force proteins that have folded up incorrectly to unfold and refold into a proper configuration. The technology may be useful in boosting production yields of recombinant, or genetically engineered, proteins, which form the basis of many biotech drugs.

The financing was led by HBM BioVentures (Cayman)and Boulder Ventures, joined by the Peierls Foundation and other seed round investors. The round’s proceeds will fund the development of the company’s drug pipeline, including an experimental treatment for multiple sclerosis.

The company’s release is here (PDF).